Navigation Links
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Date:7/22/2009

KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration (FDA). Schering-Plough is seeking marketing approval from the FDA of the mometasone furoate/formoterol fumarate combination for the maintenance treatment of asthma in patients 12 years of age and older.

Mometasone furoate/formoterol fumarate combines the active ingredients of an inhaled corticosteroid, ASMANEX((R) )(mometasone furoate inhalation powder), with the long-acting beta2-agonist, FORADIL((R)) (formoterol fumarate inhalation powder), administered via a single metered-dose inhaler. Schering-Plough has exclusive worldwide rights for the development and commercialization of the mometasone furoate and formoterol furmarate fixed-dose combination.

"We are pleased to announce the U.S. filing of the fixed-dose combination of mometasone furoate and formoterol fumarate," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "If approved by the FDA, the mometasone fuorate/formoterol combination would represent an important additional treatment option for physicians and their patients and further strengthen Schering-Plough's portfolio of respiratory products."

Combination products containing inhaled corticosteroids and long-acting beta2-agonists are the largest segment of the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) medications, in terms of dollar sales (1). The fixed-dose combination of mometasone furoate and formoterol fumarate for the treatment of asthma in patients younger than 12 years of age and for use in COPD is currently in Phase III development.

Schering-Plough is an innovation-dri
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Does your doctor know what you,re smoking?  Chances are, probably ... the over 112,000 currently registered patients under Colorado,s ... roughly 20,300+ active physicians listed with the Colorado Dept of ... though a poll in February 2014 showed 51% of ... "With marijuana legalization underway, every doctor needs ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... , August 29, 2014 ... by Product & Services (Equipment, Reagent, Primer, Probe, ... (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) ... the global Oligonucleotide Synthesis Market is expected to ... in 2014, growing at a CAGR of 9.8% ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Institute researchers are first to associate unique DNA changes ... with several types of renal cell carcinoma, ... (VAI),researchers have identified unique DNA changes in each of several ... kidney cancer in,adults. These findings could aid in the diagnosis ...
... Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ) ... the journal for,the American Society for Pharmacology and ... Vitro Metabolism of,Liquiritigenin, a Bioactive Compound Isolated from ... Liquiritigenin is one of the active compounds of ...
Cached Medicine Technology:VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 3
(Date:8/30/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... 30 August 2014: Transvenous lead extraction (TLE) is clinically ... data from the European Lead Extraction ConTRolled (ELECTRa) registry ... 2014 by Dr Maria Grazia Bongiorni, chair of the ... of cardiac implantable electronic devices (CIED) implant procedures has ... number of complications has increased and leads are often ...
(Date:8/30/2014)... The new review published by Daily Gossip ... Karen Brimeyer, who wanted to make her guide accessible to ... is now easy to find in the form of an ... the author of the new method shares all her tips ... writes in its review that the leaky gut syndrome can ...
(Date:8/30/2014)... Jake W., 18, is completing his high school degree ... Adventures transition program known as Beyond the Basics. ... actually start on a real career path,” said Jake. “ ... He has six months of sobriety under his belt after ... continue on to the Beyond the Basics transition program notes ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... PORTLAND, Ore Newly-published research by scientists at Oregon ... intake is not enough to promote significant weight loss. ... mechanism that reduces a person,s physical activity in response ... in the April edition of the American Journal ...
... will present several studies at the American Academy of ... for the treatment of multiple sclerosis (MS) and surprising ... meeting will take place April 10-17 in Toronto. , ... for 6 Months in Patients with Relapsing Multiple Sclerosis: ...
... Athletic ... , ... Brook, IL (Vocus) -- AthletiCo Physical and Occupational Therapy recently supported the ... Month) in March. The theme of this year’s NATA Month was ‘Sport Safety is ...
... cells to damaged heart tissue , TUESDAY, April 13 (HealthDay ... cells to damaged areas of animal hearts. , The strategy ... retain the cells, potentially boosting the power of cardiac stem ... a treatment for heart injuries, but 24 hours after infusion, ...
... ... OxySure has been named as a finalist in the Health category for its ... Awards recognize new companies that will have a significant impact on the environment, ... used to raise funds to support business incubation programs for technology-based entrepreneurs. ...
... note that many taking them already face higher risk ... Some anticonvulsants used to treat epilepsy and other conditions ... violent death, a new study finds. , While these ... are also approved treatments for other conditions, such as ...
Cached Medicine News:Health News:Diet alone will not likely lead to significant weight loss 2Health News:Groundbreaking MS research to be presented at American Academy of Neurology Annual Meeting 2Health News:Groundbreaking MS research to be presented at American Academy of Neurology Annual Meeting 3Health News:Athletico Raises $6,500 For Chicago Hornets Sled Hockey Team 2Health News:Athletico Raises $6,500 For Chicago Hornets Sled Hockey Team 3Health News:Magnets Might Boost Stem Cell Therapy 2Health News:OxySure Systems, Inc. Named Tech Fort Worth IMPACT Awards Finalist 2Health News:OxySure Systems, Inc. Named Tech Fort Worth IMPACT Awards Finalist 3Health News:Study Shows Some Anti-Seizure Meds Raise Suicide Risk 2Health News:Study Shows Some Anti-Seizure Meds Raise Suicide Risk 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: